about
Liver X receptors alpha and beta regulate renin expression in vivoPlasma semicarbazide-sensitive amine oxidase in human (patho)physiology.Semicarbazide-sensitive amine oxidase (SSAO): from cell to circulation.Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study.Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension.Epinephrine in the heart: uptake and release, but no facilitation of norepinephrine release.Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIaResponse to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers.Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study.Use of Impella Recover(R) LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings.Cognitive performance, symptoms and counter-regulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity.Cardiac repolarization during hypoglycaemia in type 1 diabetes: impact of basal renin-angiotensin system activity.Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure.Exogenous angiotensin II does not facilitate norepinephrine release in the heart.The sympathoadrenal system mediates the blood pressure and cardiac effects of human coagulation factor XII-related "new pressor protein".Human coagulation factor XII-related "new pressor protein": role of PACAP in its cardiovascular and sympathoadrenal effects.Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction.Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects.ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?Hemodynamic response to lower body negative pressure in hemodialysis patients.Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation.Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol.Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation beta-FXIIa?Responsivity to stress in chronic posttraumatic stress disorder due to childhood sexual abuse.Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment.Comparison of catecholamine hormone release in patients undergoing carotid artery stenting or carotid endarterectomy.Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
P50
Q33865901-49ED775D-C16B-4B17-942B-8B85ED92CA95Q35103518-1A97B557-3B59-41FD-BD55-4E9CDB5AEFEFQ36082533-1EC35EB2-33AB-472C-9F0F-BF1D52BB7F91Q36426776-3E521875-3722-4329-8C79-6A87C833F39DQ36662162-8E4EF2C2-645E-43E8-BF36-B8C1825D8027Q37364926-20D945DB-97A1-41F4-8910-6FC809F53589Q40191218-422B2F0F-8613-4A25-A9BC-5A2CD3A93CEAQ42524811-065C92AB-0C97-46F2-ADF4-29185E9998F7Q42702757-B1BEDFC2-6016-4504-9FCD-B47B6459AEAEQ42911610-390D2DE5-82AB-49CE-BE44-EDC49EC40635Q42953407-DE57081A-ECB8-42AC-A57E-A3EFB613B3D6Q43276419-D7CE973E-177F-4CD2-8A07-06E408FDE616Q43283591-78CF0BA9-869D-4066-A75B-3002764D4618Q43870329-3ACF7EA7-48E3-42D4-A374-A762F5CEFB7FQ44008845-223A5DF1-7E08-460C-AE72-C3C995DC70F1Q44167924-B803259D-F6B6-489A-90BC-BAFF81A4BBE0Q44207959-0D4ED0C5-6BAC-449C-9A31-799ABE5D62E2Q44207962-65E648BC-B91F-48B9-8CC8-F921450FE33AQ44301899-A0F437A6-E7AA-4863-AF7D-D6BB274F6B64Q44303897-55FE38D1-83BF-41DB-8099-192F3C7AC8CBQ44316911-4B737FDB-5570-47CC-A900-66DA50E46E3BQ44383396-1AFF986E-125E-4DC5-A204-177B35E0C469Q44590317-D0E39D2E-3587-4F11-9FD7-1C580E11173DQ44595548-631065F3-8909-485A-A432-4B37FDBEE64BQ44630329-5CD0DE4E-7EC7-4CE1-93CE-F318BEA81CA4Q44903708-45425C95-F095-41FB-9C99-169E2CD65BF5Q44913731-45C5DAF1-84CD-4396-ADAE-1741038F225FQ44919173-CBDD3C6C-D565-4B4F-B8F7-596D7E8B9506Q45025680-5979501F-D2CA-4485-84B4-A1CFA545D7E8
P50
description
onderzoeker
@nl
name
Frans Boomsma
@ast
Frans Boomsma
@en
Frans Boomsma
@es
Frans Boomsma
@nl
Frans Boomsma
@sl
type
label
Frans Boomsma
@ast
Frans Boomsma
@en
Frans Boomsma
@es
Frans Boomsma
@nl
Frans Boomsma
@sl
prefLabel
Frans Boomsma
@ast
Frans Boomsma
@en
Frans Boomsma
@es
Frans Boomsma
@nl
Frans Boomsma
@sl